Catheter-related bloodstream infection (CRBSI) is defined as the presence of bacteremia originating from an intravascular (I.V.) catheters. CRBSI refers to bloodstream infection attributed to an intravascular catheter by quantitative culture of the catheter tip or by differences in growth between catheter and peripheral venipuncture blood culture specimens. Also known as catheter-related sepsis, it is the most common cause of nosocomial bacteremia.
Different measures are used to reduce the risk of occurrence of CRBSI which includes the use of utmost barrier, precautions during catheter insertion, effective cutaneous anti-sepsis, and preventive strategies based on inhibiting micro-organisms originating from the skin or catheter hub from adhering to the catheter.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/chemotherapy-induced-febrile-neutropenia-market
The Catheter-Related Bloodstream Infection (CRBSI) Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Catheter-Related Bloodstream Infection (CRBSI) market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Catheter-Related Bloodstream Infection (CRBSI) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Catheter-Related Bloodstream Infection (CRBSI) Market Key Facts
-
The market size of CRBSI, in the 7MM, was USD 706.3 million in 2020.
-
Among all the 7MM countries, the US accounted for the highest market size of CRBSI, which accounts for approximately 54.93% in 2020.
-
As per DelveInsight’s estimates, the incident population of CRBSI in the 7MM was found to be 674,347, in 2020.
-
As per the analysis, in the US, the incidence of Gram-positive bacteria is more than Gram-negative bacteria, and very few are affected with candida species (fungi). Methicillin susceptible Staphylococcus aureus occupies the maximum patient pool among the Gram-positive bacteria, with 143,072 cases of this category, in 2020.
-
The estimates show a higher incidence of CRBSI in the US with 330,686 cases, in 2020.
-
Among EU5 countries, Germany accounted for the highest incidence of CRBSI with 62,368 cases in 2020. Whereas, the least number of cases was contributed by Spain with 16,793 cases.
-
France, Italy, and the UK accounted for 43,540, 32,739, and 42,570 diagnosed incident cases, respectively in 2020.
-
In 2020, Japan had 140,885 incidence cases and 135,454 diagnosed incidence cases.
Key Benefits of Catheter-Related Bloodstream Infection (CRBSI) Market Report
-
Catheter-Related Bloodstream Infection (CRBSI) market report provides an in-depth analysis of Catheter-Related Bloodstream Infection (CRBSI) Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Catheter-Related Bloodstream Infection (CRBSI) Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Catheter-Related Bloodstream Infection (CRBSI) current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Catheter-Related Bloodstream Infection (CRBSI) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Catheter-Related Bloodstream Infection (CRBSI) Market
The Catheter-Related Bloodstream Infection (CRBSI) market size is expected to increase during the forecast period owing to the expected launch of emerging therapies, along with the increasing incidence of CRBSI in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Catheter-Related Bloodstream Infection (CRBSI) market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Catheter-Related Bloodstream Infection (CRBSI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Request for Sample @ Catheter-Related Bloodstream Infection (CRBSI) Therapeutics Market Assessment
Catheter-Related Bloodstream Infection (CRBSI) Epidemiology
The epidemiology section covers insights about the historical and current Catheter-Related Bloodstream Infection (CRBSI) patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Catheter-Related Bloodstream Infection (CRBSI) Epidemiology Segmentation
-
Total Incident Population of CRBSI
-
Total Diagnosed Incident Population of CRBSI
-
Diagnosed Incidence of CRBSI by Causative Pathogens
Catheter-Related Bloodstream Infection (CRBSI) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Catheter-Related Bloodstream Infection (CRBSI) market or expected to get launched in the market during the study period. The analysis covers Catheter-Related Bloodstream Infection (CRBSI) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions
The report also covers the Catheter-Related Bloodstream Infection (CRBSI) Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Catheter-Related Bloodstream Infection (CRBSI) market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Catheter-Related Bloodstream Infection (CRBSI) emerging therapies.
Catheter-Related Bloodstream Infection (CRBSI) Companies:
-
CorMedix
-
Geistlich Pharma
-
TauroPharm GmbH
-
Fresenius Medical Care
-
Citius Pharmaceuticals
Catheter-Related Bloodstream Infection (CRBSI) Therapies:
Mino-Lok: Mino-Lok is an antibiotic lock solution used to treat patients with CLABSIs/CRBSIs. It is a combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.
Other therapies are covered in the report. Visit to get a more detailed analysis.
Table of Content
1. Key Insights
2. Executive Summary
3. Catheter-Related Bloodstream Infection (CRBSI) Competitive Intelligence Analysis
4. Catheter-Related Bloodstream Infection (CRBSI) Market Overview at a Glance
5. Catheter-Related Bloodstream Infection (CRBSI) Disease Background and Overview
6. Catheter-Related Bloodstream Infection (CRBSI) Patient Journey
7. Catheter-Related Bloodstream Infection (CRBSI) Epidemiology and Patient Population
8. Catheter-Related Bloodstream Infection (CRBSI) Treatment Algorithm, Current Treatment, and Medical Practices
9. Catheter-Related Bloodstream Infection (CRBSI) Unmet Needs
10. Key Endpoints of Catheter-Related Bloodstream Infection (CRBSI) Treatment
11. Catheter-Related Bloodstream Infection (CRBSI) Marketed Products
12. Catheter-Related Bloodstream Infection (CRBSI) Emerging Therapies
13. Catheter-Related Bloodstream Infection (CRBSI) Seven Major Market Analysis
14. Attribute Analysis
15. Catheter-Related Bloodstream Infection (CRBSI) Market Outlook (7 major markets)
16. Catheter-Related Bloodstream Infection (CRBSI) Access and Reimbursement Overview
17. KOL Views on the Catheter-Related Bloodstream Infection (CRBSI) Market.
18. Catheter-Related Bloodstream Infection (CRBSI) Market Drivers
19. Catheter-Related Bloodstream Infection (CRBSI) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/chemotherapy-induced-febrile-neutropenia-market
Latest Reports By DelveInsight
Catheter-related bloodstream infection (CRBSI) Pipeline Insights
Catheter-related bloodstream infection (CRBSI) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Catheter-Related Bloodstream Infection (CRBSI) market.
Corneal Endothelial Dystrophy Market
DelveInsight’s “Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Corneal Endothelial Dystrophy market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/